Iron Deficiency Anemia Therapy Market Insights Report: Opportunities and Drivers 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
By how much is the Iron Deficiency Anemia Therapy Market expected to grow between 2026 and 2030?
The iron deficiency anemia therapy market has shown substantial growth in recent years. This market is expected to expand from $4.78 billion in 2025 to $5.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The expansion observed historically can be attributed to the rising prevalence of iron deficiency anemia, increased understanding of anemia management, the broadening of hospital-based treatment protocols, an uptick in the use of oral iron supplements, and enhanced diagnostic screening for anemia.
The iron deficiency anemia therapy market is anticipated to experience robust expansion over the coming years. This market is projected to reach $6.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This expansion during the forecast period is driven by several factors, including a heightened demand for quicker anemia correction, an increase in chronic diseases contributing to anemia, the proliferation of specialized anemia clinics, an amplified focus on maternal and pediatric anemia care, and improvements in iron formulation technologies. Key developments anticipated during this period encompass a wider uptake of intravenous iron therapies, an increasing need for precise anemia treatments, a stronger emphasis on individualized patient therapy plans, the broader availability of oral and parenteral combined treatments, and a reinforced commitment to both the effectiveness and safety of therapies.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24265&type=smp
Which Drivers Are Influencing Market Acceleration In The Iron Deficiency Anemia Therapy Market?
The iron deficiency anemia therapy market is anticipated to experience growth due to a rising incidence of chronic diseases. These medical conditions are characterized by their long-term nature, typically enduring for a year or more. The surge in chronic diseases is linked to the increased prevalence of unhealthy lifestyle choices, such as inadequate diet, insufficient physical activity, and smoking, which foster conditions like obesity, diabetes, and heart disease, leading to protracted health complications. Chronic conditions can heighten the requirement for iron deficiency anemia therapy by impeding the body’s proper absorption of iron, consequently elevating the risk of iron deficiency and mandating supplementation or treatment to restore iron levels. For example, according to the National Health Service, a UK-based government department, it was reported in June 2024 that 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia, also known as pre-diabetes, in 2023. This figure marked an 18% increase from 3,065,825 cases recorded in 2022. Consequently, the increasing number of chronic disease cases is stimulating expansion in the iron deficiency anemia therapy market.
What Segments Are Identified Within The Structure Of The Iron Deficiency Anemia Therapy Market?
The iron deficiency anemia therapy market covered in this report is segmented –
1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide
2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types
3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology
4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users
Subsegments:
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations
2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations
3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups
4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations
Which Trends Are Shaping Activity Within The Iron Deficiency Anemia Therapy Market?
Major companies in the iron deficiency anemia therapy market are focusing on advancing treatment options, such as injectable formulations, to improve their efficacy and accessibility. A new injectable formulation refers to a recently developed or modified drug version administered via injection. For instance, in May 2023, Emcure Pharmaceuticals Ltd., an Indian-based pharmaceutical company, launched Orofer FCM 750, a formulation of ferric carboxymaltose (FCM) designed to address iron deficiency and iron deficiency anemia (IDA). Its benefits include enhanced patient compliance due to less frequent administration compared to oral supplements. The primary purpose is to effectively treat iron deficiency anemia, especially in individuals unable to tolerate oral iron supplements. This 750 mg/15 ml injectable ferric carboxymaltose received approval from India’s DCGI for iron deficiency anemia (IDA) in patients unresponsive to oral iron, particularly pregnant women with hemoglobin <10 g/dl and weight 35–70 kg. It offers a 15-minute infusion (when diluted in saline) and aligns with Anemia Mukt Bharat guidelines as a first-line treatment for severe cases.
Which Major Firms Are Strengthening Their Position In The Iron Deficiency Anemia Therapy Market?
Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc, Abbott Laboratories, Bayer AG, Pfizer Inc., Lupin Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Iron Deficiency Anemia Therapy Market?
North America was the largest region in the iron deficiency anemia therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Iron Deficiency Anemia Therapy Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24265&type=smp
Browse Through More Reports Similar to the Global Iron Deficiency Anemia Therapy Market 2026, By The Business Research Company
Hemochromatosis Iron Overload Disease Treatment Global Market Report 2026
Anemia And Other Blood Disorder Drugs Global Market Report 2026
Chemotherapy Induced Anemia Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
